Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better

Publisher： Karger

E-ISSN： 1421-9662|138|1|52-54

ISSN： 0001-5792

Source： Acta Haematologica, Vol.138, Iss.1, 2017-07, pp. : 52-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience

By  

Acta Haematologica, Vol. 138, Iss. 1, 2017-07 ,pp. : 55-60

Karger

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modern Treatment Options for Elderly Patients with Multiple Myeloma

By  

Oncology Research and Treatment, Vol. 31, Iss. 6, 2008-05 ,pp. : 335-342

Karger

Access to resources Recommend Favorite

Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 70-71

Karger

Access to resources Recommend Favorite